Raphael Dahmen

Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis

The initiation of hepatocyte-specific gene expression within embryonic hepatocytes is a stochastic event

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

Type 2 diabetes

Global aetiology and epidemiology of type 2 diabetes mellitus and its complications

Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition

Recent Advances in Insulin Therapy

Stochasticity in gene expression: from theories to phenotypes

One‐year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal‐time insulin: the EDITION 1 12‐month randomized trial, including 6‐month extension

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Pathophysiology of Type 2 Diabetes Mellitus

Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary

New Insulin Glargine 300 Units·mL−1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units·mL−1

Single‐dose new insulin glargine 300  U/ml provides prolonged, stable glycaemic control in J apanese and E uropean people with type 1 diabetes

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml

Hormonal inducibility of liver-specific enzymes in cultured rat embryos.